article thumbnail

Radiopharmaceuticals for prostate cancer to go nuclear with $6.3 bn in sales by 2030

Express Pharma

Radioligand therapies (RLTs) have received prominent attention from major pharmaceutical companies in treating prostate cancer. billion in sales by 2030, according to GlobalData. billion by 2030, far outshining Xofigo. billion by 2030. bn in sales by 2030 appeared first on Express Pharma.

article thumbnail

QMS market to value nearly $4b by 2030

European Pharmaceutical Review

According to the research, the pharmaceutical quality management systems market is projected to reach $3.97 billion by 2030. Some pharmaceutical companies are increasing their R&D spending to increase product numbers. Also noted in the report was the shift towards cloud-based systems.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Formulation development outsourcing market to be worth over $60bn by 2030

European Pharmaceutical Review

billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 Pharmaceutical companies globally are significantly investing in R&D. percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide. percent from its 2022 value of $35.1

article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 The rising requirement for small-scale and encapsulated manufacturing processes necessary to assemble these products make it challenging for many pharmaceutical companies to alter their currently installed capacity.

Dosage 98
article thumbnail

Biopharmaceuticals contributing to manufacturing outsourcing trend

European Pharmaceutical Review

Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. percent between 2022-2030. The report noted that there has been “considerable” merger and acquisition activity in recent years within the pharmaceutical contract manufacturing market.

article thumbnail

AstraZeneca’s numbers are good but trouble in China could drag it down | Nils Pratley

The Guardian - Pharmaceutical Industry

The profit figure beat forecasts and the UK pharmaceutical company raised its guidance for growth in full-year revenues and earnings from “mid-teens” to “high teens”. It all sounded like another confident step in the march to take global revenues from $46bn in 2023 to $80bn by 2030. Continue reading.

article thumbnail

Pfizer to reach carbon net-zero by 2040

European Pharmaceutical Review

In the same statement, Pfizer also announced it has signed a pledge by the US Department of Health and Human Services (HHS) that calls on US healthcare system stakeholders such as hospitals, health systems, payers, suppliers and pharmaceutical companies to reduce GHG emissions and build a more climate resilient healthcare infrastructure.